Back HIV Policy & Advocacy Global Access

Global Access

IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says

HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease

A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.

alt

Read more:

CROI 2017: Accelerated Linkage to HIV Care Improves Retention by a Third

Close to 60% of adults benefitting from point-of-care CD4 cell count testing at HIV testing sites, accelerated antiretroviral therapy (ART) initiation, and SMS appointment reminders were retained in care after 1 year, compared to just 44% of those receiving the standard of care in Mozambique, according to findings from the Engage4Health study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle.

alt

Read more:

IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives

Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.

alt

Read more:

CROI 2017: Test and Treat Study Shows Second Phase Is Finding More People with HIV

After a second wave of intensive household testing, a large study of the "test and treat" strategy in Zambia is diagnosing more people with HIV, getting more people onto treatment, and reducing the time between diagnosis and starting treatment, findings from the PopART study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2017) show.

alt

Read more:

More Articles...